A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab
Tumor mutation burden and PD-L1 represent potential predictive biomarkers for response to combination CKI therapy, while LDH and BRAF offer limited predictive value. Further work will be needed to develop a predictive nomogram to better aid in predicting potential immunotherapy benefit.
Authors
- Wolfram E. Samlowski (ORCID: https://orcid.org/0000-0002-0713-914X)
- Baylor Akhavan
Institutions
- University of Nevada, Reno (US)
- Oncology Specialists (US)
- Dermatology Specialists (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-29
- DOI
- https://doi.org/10.3389/fimmu.2026.1729883
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Nevada, Las Vegas
- National Institutes of Health